Walter A. Kukull

Walter A. Kukull

Auto-generated profile, based on publicly available information

Walter A. Kukull

National Alzheimer’s Coordinating Center, Department of Epidemiology, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1996 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DSD. Scheuner
D. Scheuner
CEC. Eckman
C. Eckman
MJM. Jensen
M. Jensen
XSX. Song
X. Song
MCM. Citron
M. Citron
SYS. Younkin
S. Younkin

1 May 2012 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
PNPeter T. Nelson
Peter T. Nelson
IAIrina Alafuzoff
Irina Alafuzoff
EBEileen H. Bigio
Eileen H. Bigio
CBConstantin Bouras
Constantin Bouras
HBHeiko Braak
Heiko Braak
TBThomas G. Beach
Thomas G. Beach
Clinicopathologic correlation studies are critically important for the field of Alzheimer disease (AD) research. Studies on human subjects with autop

3 April 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ANAdam C Naj
Adam C Naj
GJGyungah Jun
Gyungah Jun
GBGary W Beecham
Gary W Beecham
LWLi-San Wang
Li-San Wang
BVBadri Narayan Vardarajan
Badri Narayan Vardarajan
GSGerard D Schellenberg
Gerard D Schellenberg
Gerard Schellenberg and colleagues report a genome-wide association study of late-onset Alzheimer's disease (LOAD), as part of the Alzheimer Disease Genetics Consortium. They identify common variants in MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 associated with LOAD. The Alzheimer Disease Genetics Consortium (ADGC) performed a genome-wide association study of late-onset Alzheimer disease using a three-stage design consisting of a discovery stage (stage 1) and two replication stages (stages 2 and 3). Both joint analysis and meta-analysis approaches were used. We obtained genome-wide significant results at MS4A4A (rs4938933; stages 1 and 2, meta-analysis P (PM) = 1.7 × 10−9, joint analysis P (PJ) = 1.7 × 10−9; stages 1, 2 and 3, PM = 8.2 × 10−12), CD2AP (rs9349407; stages 1, 2 and 3, PM = 8.6 × 10−9), EPHA1 (rs11767557; stages 1, 2 and 3, PM = 6.0 × 10−10) and CD33 (rs3865444; stages 1, 2 and 3, PM = 1.6 × 10−9). We also replicated previous associations at CR1 (rs6701713; PM = 4.6 × 10−10, PJ = 5.2 × 10−11), CLU (rs1532278; PM = 8.3 × 10−8, PJ = 1.9 × 10−8), BIN1 (rs7561528; PM = 4.0 × 10−14, PJ = 5.2 × 10−14) and PICALM (rs561655; PM = 7.0 × 10−11, PJ = 1.0 × 10−10), but not at EXOC3L2, to late-onset Alzheimer's disease susceptibility1,2,3.

28 October 2014 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
JCJohn F. Crary
John F. Crary
JTJohn Q. Trojanowski
John Q. Trojanowski
JSJulie A. Schneider
Julie A. Schneider
JAJose F. Abisambra
Jose F. Abisambra
EAErin L. Abner
Erin L. Abner
PNPeter T. Nelson
Peter T. Nelson

17 January 2006 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
ELEric B Larson
Eric B Larson
LWLi Wang
Li Wang
JBJames D. Bowen
James D. Bowen
WMWayne C. McCormick
Wayne C. McCormick
LTLinda Teri
Linda Teri
WKWalter Kukull
Walter Kukull
Alzheimer disease and other dementing disorders are major sources of morbidity and mortality in aging societies. Proven strategies to delay onset or reduce risk for dementing disorders would be greatly beneficial. To determine whether regular exercise is associated with a reduced risk for dementia and Alzheimer disease. Prospective cohort study. Group Health Cooperative, Seattle, Washington. 1740 persons older than age 65 years without cognitive impairment who scored above the 25th percentile on the Cognitive Ability Screening Instrument (CASI) in the Adult Changes in Thought study and who were followed biennially to identify incident dementia. Baseline measurements, including exercise frequency, cognitive function, physical function, depression, health conditions, lifestyle characteristics, and other potential risk factors for dementia (for example, apolipoprotein E ϵ4); biennial assessment for dementia. During a mean follow-up of 6.2 years (SD, 2.0), 158 participants developed dementia (107 developed Alzheimer disease). The incidence rate of dementia was 13.0 per 1000 person-years for participants who exercised 3 or more times per week compared with 19.7 per 1000 person-years for those who exercised fewer than 3 times per week. The age- and sex-adjusted hazard ratio of dementia was 0.62 (95% CI, 0.44 to 0.86; P = 0.004). The interaction between exercise and performance-based physical function was statistically significant (P = 0.013). The risk reduction associated with exercise was greater in those with lower performance levels. Similar results were observed in analyses restricted to participants with incident Alzheimer disease. Exercise was measured by self-reported frequency. The study population had a relatively high proportion of regular exercisers at baseline. These results suggest that regular exercise is associated with a delay in onset of dementia and Alzheimer disease, further supporting its value for elderly persons.

1 April 2012 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
TBThomas G. Beach
Thomas G. Beach
SMSarah E. Monsell
Sarah E. Monsell
LPLeslie E. Phillips
Leslie E. Phillips
WKWalter Kukull
Walter Kukull
The neuropathologic examination is considered to provide the gold standard for Alzheimer disease (AD). To determine the accuracy of currently used cli